That is exciting! Really need some easy-to-use therapies for SLE https://t.co/inPUxiqFFd
— Dr Irwin Lim (@_connectedcare) June 15, 2018
#EULAR18 @RheumNow ABST op0241 tocilizumab may reduce the incidence of vascular complications in TAkayasu Arteritis. Failure free survival 81%, 72% and 48% at 12, 24 and at 48 months, respectively. Constitutional sx at presentation & CRP affect failure free survival
— Olga Petryna (@DrPetryna) June 15, 2018
#EULAR18 @RheumNow ABST op0236 Cohort study: risk of CVD is >3 fold higher & for CVA 8-fold higher in patients with incident AAV. HR for VTE was 3.26; significantly increased for DVT (HR 6.25), but not for PE (HR 1.33). pic.twitter.com/GwE81yzvjg
— Olga Petryna (@DrPetryna) June 15, 2018
Dr. Georg Schett presented some very cool imaging w/ Extreme CT showing that RA pts treated and responding to Tocilizumab show improvement of erosions – not true healing but filling in improved w/ disease control #EULAR18 @RheumNow ABST THU0050 pic.twitter.com/4WDwhAZflP
— Dr. John Cush (@RheumNow) June 15, 2018
Dr. Jack Cush at EULAR18 on Pathophysiology and PsA
Steroids, smoking and RF + are independent risk factors for developping opportunistic infections in RA #EULAR18 #EULAR2018 pic.twitter.com/2uECYBOaxC
— irati (@iratierreuma) June 15, 2018
Very timely as I fret I may have given myself plantar fasciitis walking around at #eular2018 @RheumNow https://t.co/Nb3BuqBi7g
— Ronan Kavanagh (@RonanTKavanagh) June 15, 2018
Dr. Jack Cush Week in Review (from EULAR)
Dr. Olga Petryna at EULAR2018: TKR and Biologic Therapy
Dr. Artie Kavanaugh at EULAR 18: Biosimilar Switching Studies
Dr. Peter Lipsky at EULAR 2018: Pegloticase “Triple” study
US physicians are more prone to continue biologics through pregnancy. Per a research poster presented at #EULAR2018 pic.twitter.com/l6VsTLe7Bs
— CreakyJoints.org (@CreakyJoints) June 15, 2018
How can life sciences organizations use #wearable technology to unlock #drugsafety information? https://t.co/xzarrrJHQJ
— Deloitte Health Care (@DeloitteHealth) June 15, 2018
Summary of cerebrovascular events in Giant Cell Arteritis
via Salvarani #Eular2018#GCA #vasculitis #stroke #CVA pic.twitter.com/GVCObFuSjL
— Dr Ai Lyn Tan (@DrAiLynTan) June 14, 2018
#Visual loss in Giant Cell Arteritis
– points to considervia Salvarani #Eular2018#GCA #vasculitis #blind #blindness #glucocorticoid #ocular pic.twitter.com/RfqjsEGJ1o
— Dr Ai Lyn Tan (@DrAiLynTan) June 14, 2018
Want to follow #rheumatologists on #twitter?
Here are over 200 rheumatologists who #tweet!
👉https://t.co/uwy0mGNDZ8If you're a rheumatologist & want to be on the list, please let me know!☺️#EULAR2018 pic.twitter.com/DpnIPLBvFC
— Dr Ai Lyn Tan (@DrAiLynTan) June 15, 2018
Osteonecrosis of the #jaw & antiresorptive treatments
👉statistics, prevalence & incidencevia Roux #EULAR2018#ONJ #mandible #fracture #bisphosphonate #bisphosphonates pic.twitter.com/QOESEY7243
— Dr Ai Lyn Tan (@DrAiLynTan) June 15, 2018
When should clinicians use US in the ES clinic? ‘I use it in the 10% with low disease activity where it might change my treatment’ – Phil Conaghan at #EULAR2018 #ultrasound
— Philip Gardiner (@PhilipGardiner) June 14, 2018
When might we use MRI in a treat to target PsA clinic? Phil Conaghan provided a good case to use MRI of hands: trials of very early PsA needed! #EULAR2018 #MRI
— Philip Gardiner (@PhilipGardiner) June 14, 2018
Are you thinking of a ‘treat to target’ approach to Psoriatic Arthritis? You’ll need the GRAPPA app (free) https://t.co/zSMomrsDO2 #EULAR2018
— Philip Gardiner (@PhilipGardiner) June 14, 2018
New differences appearing between IL17/23 blockers. Ustekinumab ineffective in axSpA studies, reason unclear #EULAR2018 #axSpA
— Philip Gardiner (@PhilipGardiner) June 15, 2018
Question from the clinic: what can I give a patient with severe axSpA and Crohn’s resistant to multiple TNFis? Sekucinumab should help axSpA but no benefit Crohn’s, Ustekinumab won’t help axSpA, will benefit Crohn’s #EULAR2018 #axSpA
— Philip Gardiner (@PhilipGardiner) June 15, 2018
Improved outcome in HCV associated cryoglobulinaemic vasculitis: long term follow up of 148 patients show high remission rates with anti-viral DAA therapy (with or without Ritux/steroids): Saadoun #EULAR2018 #vasculitis OP0235
— Philip Gardiner (@PhilipGardiner) June 15, 2018
#EULAR2018 Relative risk of post surgical infections in bDMARD users finds no difference between MOA but picks up co-prescribed steroid dose dependent significant increased risk. Pre surgery focus on reducing the prednisolone <5mg more than worrying how soon to pause the bDMARD pic.twitter.com/jRLgQXtOsN
— Patrick Kiely (@pkiely500) June 15, 2018
Off to #eular2018 to… https://t.co/XydUXOJCBS
— Olga Petryna (@DrPetryna) June 14, 2018
History of JAK inhibitors discovery elegantly presented by Van Vollenhoven actually started with investigation of children with severe immunodeficiency #EULAR2018
— Alberta Hoi (@tuna0sashimi) June 14, 2018
#EULAR2018 @RheumNow ABST op0228 Retrosp study UPenn: ⬆️ hospital readmission& prosthetic joint infect in pts on biologics who received prednisone >10 mg daily across all biologic groups. ⬆️ risk of inf w/ Actemra but too few pts to judge. Try to ⬇️ steroids before TKA. pic.twitter.com/u8qBxsSJFm
— Olga Petryna (@DrPetryna) June 15, 2018
#EULAR18 @RheumNow ABST op0229 British cohort analysis/ high biologic drug levels assoctd w/50% higher risk of infections in RA HR: 1.51; 95% CI: 1.14, 2.01). Most common in the HL group: lower (34%) & upper (16%) resp tract infect, UTIs (15%), skin inf+ shingles (8%). pic.twitter.com/XYOEMyECxl
— Olga Petryna (@DrPetryna) June 15, 2018
#eular18 @RheumNow ABST op0232 high Serum infliximab levels associates w/remission or low disease activity & effect increases over time. +RF& Female gender assoc w/ +ADA, low sIFX levels and worse outcomes. Undetectable sIFX at 21mo F vs M 35% vs 7%, p=0.006 pic.twitter.com/mxKZQY3tzi
— Olga Petryna (@DrPetryna) June 15, 2018
#EULAR18 @RheumNow ABST fri0303 Ustekinumab effective and well tolerated in SLE w/60% SRI-4 vs31% PBO. Better BILAG time to flare, improvement in MSK& mucocutaneous domains. Through wk24, 78% UST vs 67% PBO pts had ≥1 AE; 8.3% & 9.5%, respectively ≥1 SAE; no deaths. pic.twitter.com/YMh3uDt8B0
— Olga Petryna (@DrPetryna) June 15, 2018
#eular18 @RheumNow ABST op0307 IL-23i rizankizumab meets primary endpoint of ACR20 response at Wk 16 in all Rx arms ( 3 arms of 150 mg & 1 Arm 75 mg single dose).Significant improvem of mTSS vs PBO at wk24. AEs infection mainly; 2 adjudicated major CV events in RZB
— Olga Petryna (@DrPetryna) June 15, 2018
#eular2018 @RheumNow ABST op0308 Guzelkumab improves joint sx, physical funct, psoriasis, enthesitis, dactylitis& quality of life at 56 wks.6 pts w/SAEs (MI, OA, pupils unequal, radius fracture, PNA, ulcerative keratitis).1 pt neutropenia grade 3, and 6 pts had + Abs to GUS
— Olga Petryna (@DrPetryna) June 15, 2018
#EULAR18 @RheumNow ABST fri0494Specturm of visual involvement in GCA as presented by Dr. Laskou 👇 pic.twitter.com/iBQRLl2L5o
— Olga Petryna (@DrPetryna) June 15, 2018
Fun fact 58% of Amsterdam citizens aged 12 or more cycle daily in total of 881000 bikes they travel 2 million km per day but 15000 bikes are retrieved from canals annually. Not sure what happens so frequently. #EULAR2018 @RheumNow pic.twitter.com/RvjEV5mJk8
— Janet (@Janetbirdope) June 14, 2018
#GAMECHANGER why ERA pts are not achieving remission. CATCH cohort has half of women NOT in remission with 2X if obese vs 3.5X in male smokers. Only half W vs 2/3 M in remission OP0106 #EULAR2018 @RheumNow
— Janet (@Janetbirdope) June 15, 2018
Picture perfect at EULAR Amsterdam. #EULAR2018 @RheumNow pic.twitter.com/rbg2VSSQ5o
— Janet (@Janetbirdope) June 15, 2018
?New Rx for CPPD. FRI0243 poster shows in 33 pts with acute pseudogoit flares anakinra was used with resolution in 4 days. But how long to use it for and no control group. #EULAR2018 @RheumNow pic.twitter.com/qMZurSY3pm
— Janet (@Janetbirdope) June 15, 2018
Comorbidities in SpA are under recognized RCT of nurse led screen and Rx vs screen and give general education only. 250 per arm. More vaccines and bit D given but no difference in smoking cessation or cancer screening. ?worth cost. OP0304 #EULAR2018 @RheumNow pic.twitter.com/SbvYzadcTl
— Janet (@Janetbirdope) June 15, 2018
#GAMECHANGER lessons from day 2. Hydroxychloroquine may have a survival advantage in RA but could be prescribing confounding. Milder pts? 2 still mortality increase in RA. 3 siblings of RA pts have more myocardial infarct than gen population but less than RA #EULAR @RheumNow
— Janet (@Janetbirdope) June 15, 2018
What is value of tapering biologics in RA pts in remission. RCT with no difference between tapering strategies – taper csDMARDs vs biological which was TNFI. But save money with tapering biological. OP0299 #EULAR2018 @RheumNow pic.twitter.com/63cMcWy3U4
— Janet (@Janetbirdope) June 15, 2018
Ready for another great day, lots of #gout today 👏 #EULAR2018 @RheumNow pic.twitter.com/h9VB8qJveN
— Philip Robinson (@philipcrobinson) June 14, 2018
And we’re off with the crystal abstract session with a CPPD abstract #EULAR2018 @RheumNow pic.twitter.com/j2LHCFHKWb
— Philip Robinson (@philipcrobinson) June 14, 2018
Spanish data from Perez-Ruiz on 650 CPPD patients has shown HFE genotypes C282Y and H63D are associated with worse CPPD #EULAR2018 @RheumNow ABT OP0183 pic.twitter.com/6l3prucUcW
— Philip Robinson (@philipcrobinson) June 14, 2018